{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:19:59Z","timestamp":1785507599012,"version":"3.56.0"},"reference-count":40,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007496","name":"Biomedical Laboratory Research and Development, VA Office of Research and Development","doi-asserted-by":"publisher","award":["1I01BX005765"],"award-info":[{"award-number":["1I01BX005765"]}],"id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol Myers Squibb Pharmaceutical","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,3,6]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Muscle-invasive urothelial cancer (UC) has a high risk of recurrence after definitive treatment. Nivolumab adjuvant to radical surgery improves disease-free survival in patients with UC with a high risk of recurrence; however, its role adjuvant to chemoradiation therapy (CRT) is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The NEXT trial is a single-arm, phase-2 study evaluating the efficacy and tolerability of nivolumab adjuvant to CRT in patients with localized or locoregional UC. The primary endpoint is failure-free survival (FFS) at 2 years. Secondary endpoints include patterns of recurrence, toxicity and quality of life (QoL). Plasma cell-free DNA (cfDNA) was subjected to shallow whole-genome sequencing to correlate with outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>28 patients were enrolled and received 480\u2009mg of nivolumab intravenously every 4 weeks for up to 12 cycles adjuvant to CRT. The FFS at 2\u2009years was 33.2% (95% CI 18.5% to 59.6%). Nine (32%) patients had localized progression, and eight (29%) had distant progression. 25 (89%) had one or more high-risk features (ie, plasmacytoid differentiation, T4, N+, multiple tumors, tumors &gt;5\u2009cm, residual disease before CRT, carcinoma in situ, and hydronephrosis). Patients with \u22642 high-risk features had a median FFS of 45.2 months (95%\u2009CI 14.56 to not reached (NR)) compared with 8.2 months (95%\u2009CI 7.1 to NR) in those with three or more risk features (p=0.0024). Nivolumab-associated treatment-related adverse events occurred in 18 (64.3%) patients, only 3 had grade 3 TRAEs, with significant changes in QoL. Plasma cfDNA copy number instability (CNI) scores \u226425 before the first dose of adjuvant nivolumab and at cycle 4 were associated with better overall survival compared with CNI scores \u226526 (49.6 months vs 20.5 months, p=0.0024). Genome copy number changes indicated chromatin remodeling and tyrosine kinase pathways, among others, as oncogenic drivers implicated in progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nivolumab adjuvant to CRT in localized or locally advanced UC is well tolerated. Stratification by risk factors and correlation with plasma cfDNA analyses generate hypotheses for potential patient selection and putative therapeutic targets for future study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03171025\">NCT03171025<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-010572","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T21:20:43Z","timestamp":1742332843000},"page":"e010572","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03171025","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03171025","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03775265","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1084-953X","authenticated-orcid":false,"given":"Gliceida M.","family":"Galarza Fortuna","sequence":"first","affiliation":[{"name":"University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grass","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L","family":"Maughan","sequence":"additional","affiliation":[{"name":"University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit K","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dechet","sequence":"additional","affiliation":[{"name":"University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Beck","sequence":"additional","affiliation":[{"name":"Oncocyte Corporation, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekke","family":"Schuetz","sequence":"additional","affiliation":[{"name":"Oncocyte Corporation, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Sanchez","sequence":"additional","affiliation":[{"name":"University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock","family":"O\u2019Neil","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Urology, University of Utah Health, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Poch","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Center Inc, Tampa, Florida, USA"},{"name":"Immunology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tward","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenzin","family":"Phunrab","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-4598","authenticated-orcid":false,"given":"Josiah Lyn","family":"Hawks","sequence":"additional","affiliation":[{"name":"Research Compliance Office, University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3518-0411","authenticated-orcid":false,"given":"Umang","family":"Swami","sequence":"additional","affiliation":[{"name":"Department of Oncology, Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M","family":"Boucher","sequence":"additional","affiliation":[{"name":"University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-0831","authenticated-orcid":false,"given":"Sumati","family":"Gupta","sequence":"additional","affiliation":[{"name":"University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"2026052722304360000_13.3.e010572.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026052722304360000_13.3.e010572.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"2026052722304360000_13.3.e010572.3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","article-title":"A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer","volume":"25","author":"Yang","year":"2016","journal-title":"Surg Oncol"},{"key":"2026052722304360000_13.3.e010572.4","first-page":"939","article-title":"Bladder cancer in the elderly patient: challenges and solutions","volume":"10","author":"Guancial","year":"2015","journal-title":"Clin Interv Aging"},{"key":"2026052722304360000_13.3.e010572.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00170-5"},{"key":"2026052722304360000_13.3.e010572.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.5548"},{"key":"2026052722304360000_13.3.e010572.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106106"},{"key":"2026052722304360000_13.3.e010572.8","doi-asserted-by":"crossref","first-page":"16109","DOI":"10.1200\/jco.2008.26.15_suppl.16109","article-title":"Concurrent weekly cisplatin during radiation treatment of locally advanced bladder carcinoma in elderly patients","volume":"26","author":"Jouhadi","year":"2008","journal-title":"JCO"},{"key":"2026052722304360000_13.3.e010572.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"2026052722304360000_13.3.e010572.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"2026052722304360000_13.3.e010572.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30065-7"},{"key":"2026052722304360000_13.3.e010572.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"2026052722304360000_13.3.e010572.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2014.07.004"},{"key":"2026052722304360000_13.3.e010572.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"2026052722304360000_13.3.e010572.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125"},{"key":"2026052722304360000_13.3.e010572.16","first-page":"86","article-title":"Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index","volume":"11","author":"Jensen","year":"2013","journal-title":"J Support Oncol"},{"key":"2026052722304360000_13.3.e010572.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0231"},{"key":"2026052722304360000_13.3.e010572.18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/bco2.108","article-title":"Outcomes of poorly differentiated and plasmacytoid variant bladder urothelial carcinoma","volume":"3","author":"Lockhart","year":"2022","journal-title":"BJUI Compass"},{"key":"2026052722304360000_13.3.e010572.19","doi-asserted-by":"crossref","unstructured":"Matulay JT , Kamat AM . Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Res 2018;7. doi:10.12688\/f1000research.14903.1","DOI":"10.12688\/f1000research.14903.1"},{"key":"2026052722304360000_13.3.e010572.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222223","article-title":"Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: A meta-analysis","volume":"14","author":"Zhu","year":"2019","journal-title":"PLoS One"},{"key":"2026052722304360000_13.3.e010572.21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006551","article-title":"Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023","volume":"11","author":"Joshi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026052722304360000_13.3.e010572.22","doi-asserted-by":"crossref","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2046","article-title":"1961O Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: A phase II, randomized study by the Hellenic GU Cancer Group","volume":"35","author":"Kougioumtzopoulou","year":"2024","journal-title":"Ann Oncol"},{"key":"2026052722304360000_13.3.e010572.23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"2026052722304360000_13.3.e010572.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"2026052722304360000_13.3.e010572.25","first-page":"336","article-title":"A new standard of care for advanced-stage urothelial carcinoma","volume":"21","author":"Sidaway","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026052722304360000_13.3.e010572.26","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","article-title":"Signatures of copy number alterations in human cancer","volume":"606","author":"Steele","year":"2022","journal-title":"Nature New Biol"},{"key":"2026052722304360000_13.3.e010572.27","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3892\/ijo.2017.3893","article-title":"Gene expression profiling in bladder cancer identifies potential therapeutic targets","volume":"50","author":"Hussain","year":"2017","journal-title":"Int J Oncol"},{"key":"2026052722304360000_13.3.e010572.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018255","article-title":"Spotlight on differentially expressed genes in urinary bladder cancer","volume":"6","author":"Zaravinos","year":"2011","journal-title":"PLoS One"},{"key":"2026052722304360000_13.3.e010572.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026052722304360000_13.3.e010572.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"key":"2026052722304360000_13.3.e010572.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.08.082"},{"key":"2026052722304360000_13.3.e010572.32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS585","article-title":"Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3)","volume":"40","author":"Sonpavde","year":"2022","journal-title":"JCO"},{"key":"2026052722304360000_13.3.e010572.33","unstructured":"G1 Therapeutics . G1 therapeutics providesthird quarter 2023 financial results and operational highlights. 2023."},{"key":"2026052722304360000_13.3.e010572.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-018-0044-4"},{"key":"2026052722304360000_13.3.e010572.35","doi-asserted-by":"crossref","unstructured":"Tate T , Plumber SA , Al-Ahmadie H . Combined mek inhibition and pparg activation eradicates muscle invasive bladder cancer in a mouse model of BBN-induced carcinogenesis. bioRxiv [Preprint] 2023. doi:10.1101\/2023.08.19.553961","DOI":"10.1101\/2023.08.19.553961"},{"key":"2026052722304360000_13.3.e010572.36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature New Biol"},{"key":"2026052722304360000_13.3.e010572.37","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41591-024-03091-7","article-title":"Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial","volume":"30","author":"Powles","year":"2024","journal-title":"Nat Med"},{"key":"2026052722304360000_13.3.e010572.38","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2045","article-title":"1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial","volume":"35","author":"Bjerggaard Jensen","year":"2024","journal-title":"Ann Oncol"},{"key":"2026052722304360000_13.3.e010572.39","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1200\/JCO.2021.39.6_suppl.428","article-title":"INTACT (S\/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients","volume":"39","author":"Singh","year":"2021","journal-title":"JCO"},{"key":"2026052722304360000_13.3.e010572.40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS720","article-title":"Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC)","volume":"42","author":"Gupta","year":"2024","journal-title":"JCO"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:31:13Z","timestamp":1779946273000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,18]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/jitc-2024-010572"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010572","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}